The FDA highlights high death rates and questions overall survival for Carvykti and Abecma.

Brutal FDA briefing documents raise questions about the approvability of imetelstat for myelodysplastic syndromes.

Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.

Of the big oncology deals since 2016, there are still plenty that could go either way.

Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

A look at big oncology deals since 2016 suggests that there have been more duds than successes.

Lifileucel heads up the list of upcoming US FDA catalysts.